Czech National Bank Raises Stock Position in Merck & Co., Inc. $MRK

Czech National Bank raised its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 3.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 654,472 shares of the company’s stock after acquiring an additional 20,087 shares during the quarter. Czech National Bank’s holdings in Merck & Co., Inc. were worth $68,890,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in MRK. Chemung Canal Trust Co. grew its holdings in Merck & Co., Inc. by 21.1% during the 3rd quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company’s stock valued at $6,407,000 after buying an additional 13,285 shares in the last quarter. First Pacific Financial lifted its holdings in shares of Merck & Co., Inc. by 14.7% in the third quarter. First Pacific Financial now owns 47,555 shares of the company’s stock worth $3,991,000 after buying an additional 6,082 shares in the last quarter. Diversified Trust Co lifted its holdings in shares of Merck & Co., Inc. by 9.6% in the third quarter. Diversified Trust Co now owns 207,838 shares of the company’s stock worth $17,444,000 after buying an additional 18,187 shares in the last quarter. Caxton Associates LLP boosted its position in shares of Merck & Co., Inc. by 23.3% during the second quarter. Caxton Associates LLP now owns 39,421 shares of the company’s stock worth $3,121,000 after acquiring an additional 7,458 shares during the last quarter. Finally, Coldstream Capital Management Inc. boosted its position in shares of Merck & Co., Inc. by 12.7% during the third quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock worth $10,364,000 after acquiring an additional 13,940 shares during the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck agreed to acquire Terns Pharmaceuticals for $53.00 per share (~$6.7B) to add TERN-701, an allosteric BCR::ABL1 candidate for chronic myeloid leukemia — seen as a strategic, near-term pipeline boost ahead of Keytruda patent risk. Merck to Acquire Terns Pharmaceuticals press release
• Positive Sentiment: Analysts highlight TERN-701’s disruptive potential in CML; some firms say the deal strengthens Merck’s long-term oncology franchise and could be accretive if the asset delivers. Health Care Roundup: Market Talk
• Positive Sentiment: Broker action: Citi recently raised its price target on MRK to $125 (from $120), signaling continued analyst support amid the M&A and pipeline moves. Citi Raises its Price Target on Merck
• Positive Sentiment: Market backdrop helped equities broadly: risk-on sentiment (hopes for a ceasefire in the Middle East) and lower oil prices supported healthcare stocks, including MRK. Equities Rise, Oil Dips as Traders Weigh Prospects of Iran War Ceasefire
• Neutral Sentiment: Merck announced a multi‑year collaboration with Quotient Therapeutics on IBD target discovery (potential upside, but long‑term and milestone‑driven). Quotient Therapeutics Announces Collaboration with Merck
• Neutral Sentiment: Merck hosted/announced investor and M&A calls to discuss the transaction and strategy — useful for details but not an immediate catalyst beyond confirmation of deal terms. Merck & Co., Inc. (MRK) M&A Call Transcript
• Negative Sentiment: Deal risks: reporting notes potential for a bidding contest or activist interest — that could raise acquisition cost or create execution risk; investors may watch for how Merck finances / integrates the asset. Why Merck Might Have A Fight On Its Hands With Its $6.7 Billion Takeover Of Terns

Insider Activity

In related news, EVP Richard R. Deluca sold 37,685 shares of the stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $120.92, for a total value of $4,556,870.20. Following the completion of the transaction, the executive vice president owned 160,174 shares of the company’s stock, valued at approximately $19,368,240.08. This trade represents a 19.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David Michael Williams sold 5,000 shares of Merck & Co., Inc. stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $121.91, for a total value of $609,550.00. Following the completion of the transaction, the executive vice president owned 30,838 shares of the company’s stock, valued at approximately $3,759,460.58. This represents a 13.95% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 320,176 shares of company stock worth $38,281,735. 0.13% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. TD Cowen lifted their price target on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a report on Tuesday, January 20th. Royal Bank Of Canada initiated coverage on shares of Merck & Co., Inc. in a report on Wednesday, February 25th. They set an “outperform” rating and a $142.00 price objective for the company. Zacks Research upgraded Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Scotiabank lifted their target price on Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “sector outperform” rating in a report on Thursday, December 4th. Finally, Morgan Stanley boosted their target price on Merck & Co., Inc. from $100.00 to $102.00 and gave the stock an “equal weight” rating in a research report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $127.13.

Merck & Co., Inc. Trading Up 2.5%

MRK stock opened at $119.33 on Thursday. The firm has a fifty day moving average price of $116.27 and a 200 day moving average price of $101.44. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14. The firm has a market cap of $295.04 billion, a PE ratio of 16.39, a price-to-earnings-growth ratio of 2.25 and a beta of 0.27. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. During the same quarter in the prior year, the firm earned $1.72 earnings per share. Merck & Co., Inc.’s revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Sell-side analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.